Risk Factors Update Summary
- The number of outstanding shares increased from 48 million to 65 million.
- The accumulated deficit rose from $235.4 million to $348.4 million.
- Future milestone payments from GSK increased to $475 million for each POLQ and WRN product.
- The number of employees increased from 103 to 124 as of December 31, 2023.
- The company will need to comply with Section 404 requirements for internal control over financial reporting.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1676725&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.